ARTICLE | Clinical News
RT002: Ph III started
December 30, 2016 10:07 PM UTC
Revance began a pair of double-blind, placebo-controlled, North American Phase III trials to evaluate single injections of RT002 in about 600 total patients. The trials are part of the company’s Phase...
BCIQ Company Profiles